BDMD vs NMTC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 3/9, indicating poor financial health. Despite a seemingly reasonable Price/Book of 0.77 and a strong Gross Margin of 86.94%, the company is deeply unprofitable with negative operating and net margins, collapsing revenue, and no analyst coverage. The complete absence of Altman Z-Score and intrinsic value calculations, combined with a 5-year return of -89.3%, signals severe distress. Technical indicators and insider sentiment are also weak, reinforcing a high-risk outlook.
NMTC presents a contradictory profile with a stable Piotroski F-Score of 6/9 and a very strong liquidity position (Current Ratio 6.41), yet it suffers from severe operational decay. The company is experiencing negative revenue growth (-11.70% YoY) and deep losses, evidenced by an ROE of -146.27%. While the balance sheet is clean with minimal debt (D/E 0.04), the bearish technical trend and consistent lack of profitability make it a high-risk speculative play.
Compare Another Pair
Related Comparisons
BDMD vs NMTC: Head-to-Head Comparison
This page compares Baird Medical Investment Holdings Limited (BDMD) and NeuroOne Medical Technologies Corporation (NMTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.